X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17349) 17349
Book Review (1907) 1907
Publication (1251) 1251
Newsletter (46) 46
Magazine Article (40) 40
Book Chapter (27) 27
Conference Proceeding (14) 14
Trade Publication Article (4) 4
Book / eBook (2) 2
Dissertation (2) 2
Paper (2) 2
Web Resource (2) 2
Data Set (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (16100) 16100
humans (11073) 11073
male (10471) 10471
animals (7616) 7616
piperazines - pharmacology (7242) 7242
female (5816) 5816
piperazines - administration & dosage (5661) 5661
piperazines - therapeutic use (5617) 5617
rats (4242) 4242
adult (4025) 4025
middle aged (3990) 3990
pharmacology & pharmacy (3920) 3920
imatinib mesylate (3042) 3042
piperazines - adverse effects (2738) 2738
dose-response relationship, drug (2644) 2644
sildenafil citrate (2586) 2586
aged (2579) 2579
benzamides (2479) 2479
treatment outcome (2301) 2301
mice (2264) 2264
neurosciences (2192) 2192
oncology (1917) 1917
pyrimidines - therapeutic use (1610) 1610
psychiatry (1608) 1608
pyrimidines - administration & dosage (1545) 1545
rats, sprague-dawley (1505) 1505
time factors (1491) 1491
abridged index medicus (1422) 1422
sildenafil (1398) 1398
administration, oral (1378) 1378
piperazines - pharmacokinetics (1327) 1327
purines (1245) 1245
sulfones (1236) 1236
antineoplastic agents - therapeutic use (1204) 1204
drug therapy (1173) 1173
hematology (1091) 1091
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1084) 1084
adolescent (1062) 1062
rats, wistar (1050) 1050
double-blind method (1029) 1029
analysis (984) 984
imatinib (976) 976
research (975) 975
care and treatment (948) 948
drug administration schedule (939) 939
erectile dysfunction - drug therapy (931) 931
cancer (928) 928
pyrimidines - pharmacology (893) 893
aripiprazole (884) 884
antineoplastic agents - administration & dosage (881) 881
serotonin (878) 878
drug therapy, combination (855) 855
disease models, animal (854) 854
serotonin antagonists - pharmacology (839) 839
therapy (835) 835
pyridines - pharmacology (819) 819
erectile dysfunction (808) 808
drug interactions (791) 791
double-blind (773) 773
medicine & public health (773) 773
antipsychotic agents - therapeutic use (761) 761
efficacy (756) 756
chronic myelogenous leukemia (746) 746
schizophrenia (746) 746
piperazines - chemistry (728) 728
chronic myeloid-leukemia (713) 713
pyrimidines - adverse effects (701) 701
rat (700) 700
young adult (699) 699
urology & nephrology (695) 695
cardiac & cardiovascular systems (687) 687
serotonin receptor agonists - pharmacology (680) 680
clinical neurology (662) 662
cell line, tumor (660) 660
clinical trials as topic (654) 654
sulfones - therapeutic use (646) 646
health aspects (638) 638
dosage and administration (637) 637
aged, 80 and over (635) 635
piperazines - metabolism (626) 626
pharmacokinetics (623) 623
blood pressure - drug effects (622) 622
antipsychotic agents - adverse effects (621) 621
brain (610) 610
behavior, animal - drug effects (609) 609
article (607) 607
phosphodiesterase inhibitors - therapeutic use (597) 597
expression (593) 593
motor activity - drug effects (585) 585
sulfones - administration & dosage (579) 579
protein kinase inhibitors - therapeutic use (578) 578
apoptosis (573) 573
schizophrenia - drug therapy (572) 572
pharmacology (571) 571
piperazines - blood (570) 570
antineoplastic agents - pharmacology (566) 566
purines - therapeutic use (558) 558
biochemistry & molecular biology (555) 555
dopamine (553) 553
drug synergism (553) 553
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16459) 16459
Japanese (229) 229
German (174) 174
Russian (153) 153
French (144) 144
Chinese (70) 70
Italian (58) 58
Spanish (42) 42
Hungarian (23) 23
Polish (20) 20
Swedish (17) 17
Danish (13) 13
Norwegian (12) 12
Portuguese (11) 11
Dutch (8) 8
Turkish (6) 6
Czech (4) 4
Bulgarian (2) 2
Hebrew (2) 2
Ukrainian (2) 2
Croatian (1) 1
Finnish (1) 1
Lithuanian (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 08/2015, Volume 21, Issue 16, pp. 3705 - 3715
Purpose: Bruton's tyrosine kinase (BTK) is a critical enzyme in the B-cell receptor pathway and is inhibited by ibrutinib due to covalent binding to the kinase... 
B-CELL RECEPTOR | TUMOR PROLIFERATION | BRUTONS TYROSINE KINASE | CLL | ONCOLOGY | BCL-2 INHIBITOR | INITIAL THERAPY | IN-VIVO | PCI-32765 | KINASE INHIBITOR IBRUTINIB | SINGLE-ARM | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Apoptosis - drug effects | Humans | Neoplastic Cells, Circulating - metabolism | Male | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Purines - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Protein-Tyrosine Kinases - genetics | Female | bcl-X Protein - biosynthesis | Protein-Tyrosine Kinases - biosynthesis | B-Cell Activating Factor - biosynthesis | Neoplastic Cells, Circulating - drug effects | Pyrimidines - administration & dosage | Gene Expression Regulation, Leukemic - drug effects | Nitrophenols - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - biosynthesis | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Pyrazoles - administration & dosage | B-Cell Activating Factor - genetics | Biphenyl Compounds - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Isoquinolines - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - genetics | Sulfonamides - administration & dosage | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer | Index Medicus
Journal Article
Journal Article
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 7, pp. 1214 - 1221
From 2001 to 2011, 122 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia were treated with chemotherapy + imatinib (n... 
ADULT PATIENTS | HYPER-CVAD | GENE REARRANGEMENTS | STANDARD-RISK | QUANTIFICATION | ACUTE LYMPHOBLASTIC-LEUKEMIA | FLOW-CYTOMETRY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | CLINICAL-SIGNIFICANCE | Piperazines - administration & dosage | Cyclophosphamide - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Thiazoles - administration & dosage | Neoplasm Recurrence, Local - mortality | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Benzamides - administration & dosage | Flow Cytometry | Neoplasm, Residual - diagnosis | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Neoplasm, Residual - mortality | Philadelphia Chromosome | Real-Time Polymerase Chain Reaction | Doxorubicin - administration & dosage | Dasatinib | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Pyrimidines - administration & dosage | RNA, Messenger - genetics | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Remission Induction | Cytarabine - administration & dosage | Neoplasm, Residual - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | Immunoglobulin Heavy Chains - genetics | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia
Journal Article
European Heart Journal, ISSN 0195-668X, 2014, Volume 35, Issue 34, pp. 2285 - 2294
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EXEMESTANE | ONCOLOGY | CELL-CYCLE | POSTMENOPAUSAL WOMEN | HER2 | PLUS | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer | Index Medicus
Journal Article
Neuropharmacology, ISSN 0028-3908, 08/2013, Volume 71, pp. 83 - 97
Serotonin (5-HT) is a neurotransmitter that is involved in many behavioral functions, including the organization of defense, and its putative pathological... 
Fear | Zebrafish | Anxiety | Serotonin | Scototaxis | Geotaxis | 5-HYDROXYTRYPTAMINE RELEASE | RAT | 5-HT1A RECEPTOR ANTAGONISTS | REUPTAKE INHIBITORS | DORSAL RAPHE | ADULT ZEBRAFISH | ELEVATED PLUS-MAZE | T-MAZE | NEUROSCIENCES | IN-VIVO | PHARMACOLOGY & PHARMACY | BRAIN | Anti-Anxiety Agents - administration & dosage | Fenclonine - administration & dosage | Spiro Compounds - therapeutic use | Anxiety - drug therapy | Piperidones - therapeutic use | Serotonin - chemistry | Brain - metabolism | Pyridines - adverse effects | Fenclonine - adverse effects | Behavior, Animal - drug effects | Hyperkinesis - chemically induced | Neurons - metabolism | Serotonin 5-HT1 Receptor Antagonists - administration & dosage | Anti-Anxiety Agents - therapeutic use | Buspirone - therapeutic use | Fluoxetine - adverse effects | Disease Models, Animal | Pyridines - administration & dosage | Nerve Tissue Proteins - agonists | Piperazines - therapeutic use | Piperazines - adverse effects | Extracellular Fluid - drug effects | Brain - drug effects | Serotonin Uptake Inhibitors - administration & dosage | Fluoxetine - administration & dosage | Piperazines - administration & dosage | Fenclonine - therapeutic use | Spiro Compounds - administration & dosage | Piperidones - adverse effects | Hyperkinesis - metabolism | Spiro Compounds - adverse effects | Dose-Response Relationship, Drug | Buspirone - administration & dosage | Protein Isoforms - metabolism | Protein Isoforms - agonists | Anti-Anxiety Agents - adverse effects | Buspirone - adverse effects | Fluoxetine - therapeutic use | Neurons - drug effects | Anxiety - metabolism | Pyridines - therapeutic use | Nerve Tissue Proteins - antagonists & inhibitors | Serotonin Uptake Inhibitors - therapeutic use | Serotonin Uptake Inhibitors - adverse effects | Serotonin 5-HT1 Receptor Agonists - therapeutic use | Serotonin 5-HT1 Receptor Agonists - adverse effects | Serotonin 5-HT1 Receptor Antagonists - adverse effects | Nerve Tissue Proteins - metabolism | Piperidones - administration & dosage | Extracellular Fluid - metabolism | Serotonin 5-HT1 Receptor Antagonists - therapeutic use | Animals | Serotonin - metabolism | Serotonin 5-HT1 Receptor Agonists - administration & dosage | Anxiety - chemically induced | Protein Isoforms - antagonists & inhibitors | Phenols | Buspirone hydrochloride | Fluoxetine | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2155 - 2166
Patients who had received a drug-eluting stent and then dual antiplatelet therapy for 12 months were randomly assigned to 18 more months of therapy or aspirin... 
TRIALS | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | MULTICENTER | CLOPIDOGREL | TICAGRELOR | THROMBOSIS | RATIONALE | PREVENTION | ASPIRIN | CLINICAL-OUTCOMES | Piperazines - administration & dosage | Prasugrel Hydrochloride | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Aspirin - administration & dosage | Incidence | Time Factors | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Myocardial Ischemia - mortality | Thrombosis - prevention & control | Drug Therapy, Combination | Myocardial Ischemia - epidemiology | Platelet Aggregation Inhibitors - adverse effects | Drug-Eluting Stents | Drug Administration Schedule | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Myocardial Ischemia - therapy | Aged | Hemorrhage - chemically induced | Aggregation | Treatment outcome | Care and treatment | Usage | Blood platelets | Analysis | Drug-eluting stents | Dosage and administration | Cardiovascular diseases | Thrombosis | Health aspects | Blood clot | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Drug delivery | Patients | Bleeding | Clinical outcomes | Cerebrovascular system | Coronary vessels | Implants | Clopidogrel | Drug therapy | Stents | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2010, Volume 55, Issue 18, pp. 1915 - 1922
Journal Article